Content area
Full Text
Eli Lilly ($LLY) has ratcheted up its international fight with Canada over what it considers unfair patent rulings. The Indianapolis, IN-based Lilly has now filed a $500 million lawsuit against the Canadian government alleging its patent laws are inconsistent and permitted generics of some of Lilly's drugs to hit the market sooner than they should have.
"Patent decisions in Canada over the last decade not only fly in the face of long-established international standards, but they're subjective and completely unpredictable. The standard seems to be that there is no standard," Doug Norman, general patent counsel for Lilly said in a statement, according to ABC News in Indianapolis.
The case was...